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Adoptive therapy with chimeric antigen receptor (CAR)-redirectedT cells showed spectac-
ular efficacy in the treatment of leukemia in recent early phase trials. Patient’sT cells were
ex vivo genetically engineered with a CAR, amplified and re-administered to the patient.
While T cells mediating the primary response were predominantly of young effector and
central memory phenotype, repetitive antigen engagement irreversible triggersT cell mat-
uration leaving late memory cells with the KLRG1+ CD57+ CD7− CCR7− phenotype in
the long-term. These cells preferentially accumulate in the periphery, are hypo-responsive
uponTCR engagement and prone to activation-induced cell death. A recent report indicates
that those T cells can be rescued by CAR provided CD28 and OX40 (CD134) stimulation.
We discuss the strategy with respect to prolong the anti-tumor response and to improve
the over-all efficacy of adoptive cell therapy.
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ADOPTIVE THERAPY WITH CAR ENGINEERED T CELLS
SHOWED SPECTACULAR EFFICACY IN EARLY PHASE TRIALS
Recent success in the immune therapy of malignant diseases has
sustained the promise that the immune system can control can-
cer in the long-term. On the other hand, tumor-specific T cells
are rare in cancer patients making their isolation and ex vivo
amplification to therapeutic numbers necessary. To overcome the
situation strategies were developed to engraft T cells with defined
specificity by genetic engineering; the so-called “T-body” strat-
egy equips patient’s T cells with a recombinant trans-membrane
receptor molecule which is composed in the extracellular part of an
antibody-type recognition domain for MHC-independent bind-
ing and in the intracellular part of T cell activating domains, mostly
the TCR CD3ζ endodomain linked to a costimulatory domain like
CD28, OX40, or 4-1BB (Gross and Eshhar, 1992; Eshhar, 2008).
Such a chimeric antigen receptor (CAR) redirects T cells in an
antigen-specific fashion producing specific T cell activation toward
defined targets.
Second generation CAR’s providing CD28 costimulation along
with the primary CD3ζ signal more effectively activate T cells
than CAR’s with CD3ζ signaling only. This is basically due to
the CD28 mediated improvement of T cell effector functions
and the protection from activation-induced cell death resulting
in prolonged persistence in vivo (Savoldo et al., 2011). Other
costimulatory domains of the CD28 family, like 4-1BB (CD137),
also improves T cell persistence (Milone et al., 2009; Song et al.,
2011). Each individual costimulatory signal, however, differen-
tially orchestrates the effector functions including cytokine secre-
tion, amplification, and cytolytic activity (Hombach and Abken,
2011) which allows to modulate the anti-tumor response in a
fine-tuned fashion.
Current clinical trials are utilizing second generation CARs
to ensure prolonged persistence of engineered T cells in vivo. T
cells engineered with a 4-1BB-ζ CAR targeting CD19 recently pro-
duced spectacular efficacy toward refractory leukemia in patients
with high tumor burden (Kalos et al., 2011; Grupp et al., 2013).
Further studies in other centers are also reporting encouraging
clinical responses using CD28-ζCAR T cells (Brentjens et al., 2011;
Kochenderfer et al., 2012). The general success of these studies is
likely due to repetitive tumor cell killing by CAR T cells; addition-
ally, the targeted CD19 is also expressed by healthy B cells which
re-stimulate the CAR T cells independently of the targeted tumor
cells. The situation in targeting solid tumors, however, is more
complex, in particular with respect to immune repression, and
may require supporting strategies as discussed in a recent review
(Gilham et al., 2012). We here address an additional aspect which
is attracting increasing attention and which is of equal relevance
for the success in adoptive cell therapy: the progression of CAR
redirected T cells into terminal maturation upon repetitive antigen
encounter.
REPETITIVE CAR ENGAGEMENT PRODUCES LATE EFFECTOR
MEMORY CELLS WITH ALTERED FUNCTIONAL CAPACITIES
Chimeric antigen receptor engineered young T cells, the majority
of them with central memory phenotype, are adoptively trans-
ferred to the patient since these cells showed superior in medi-
ating an anti-tumor response in pre-clinical models (Klebanoff
et al., 2005). Repetitive binding to cognate antigen, however,
induces CAR T cells to amplify, as T cells physiologically do
upon TCR/CD28 engagement or TCR stimulation in presence
of IL-2. Extensive amplification, however, substantially impacts
the anti-tumor efficacy of CAR T cells in the long-term. After
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<2 weeks of cell divisions in vitro, T cells progress in matura-
tion and alter their functional properties, associated by a change
in phenotype (Figure 1). Repetitive antigen engagement converts
naïve and central memory T cells to cells with a CCR7− CD62Llow
CD57+ KLRG1+ effector memory phenotype with CD45ROhigh
CD45RAlow and CD27low CD28low expression. CAR mediated
maturation occurs in both CD8+ and CD4+ T cells and does
not happen when cell division is blocked. The process is observed
in a mouse tumor model in which after adoptive transfer of young
CCR7+ CAR T cells the majority of tumor infiltrating CAR T cells
are of CCR7low phenotype (Hombach et al., 2013). One conse-
quence is that the capacity of those cells to re-enter the lymph
and to re-circulate is diminished since CCR7 is required for T
cell homing into secondary lymphoid organs (Sallusto et al., 1999;
Müller and Lipp, 2003; Bromley et al., 2005; Klebanoff et al., 2005;
Moschovakis and Förster, 2012). Inability of CCR7− T cells to
re-circulate, on the other hand, may be of advantage since most
solid cancer lesions occur in the periphery. The assumption is
sustained by the observation that CCR7− CAR T cells persist in
higher numbers in the tumor lesion although both the CCR7+
and CCR7− subset T cells equally efficiently target to the tumor
(Hombach et al., 2013). Paradoxically, the anti-tumor response of
CCR7− CAR T cells is less efficient than that of CCR7+ T cells
when redirected by a CD28-ζ CAR. This is moreover unexpected
since CCR7− T cells secrete higher amounts of pro-inflammatory
cytokines like IFN-γ and harbor higher levels of cytolytic effec-
tor molecules like perforin and granzymes compared to CCR7+
T cells. Detailed analyses revealed that CCR7− T cells are prone
to spontaneous and activation-induced cell death which is insuf-
ficiently prevented by CAR mediated CD28 costimulation (Hom-
bach et al., 2013). Similar observations were reported for CD57+
T cells (Chattopadhyay et al., 2009) and which is in contrast to
CCR7+ T cells.
Simultaneous CD28 and OX40 costimulation reduces the
high propensity of CCR7− T cells to undergo apoptosis (Hom-
bach et al., 2013). OX40 promotes Bcl-xL and Bcl-2 expression,
enhances the survival of antigen-experienced effector T cells and
improves the generation of antigen-specific T cell memory (Rogers
FIGURE 1 |T cell maturation is accompanied by altered functional
properties. CAR engineered T cells progress in maturation when the CAR
repetitively engages cognate antigen as physiologically occurs upon
TCR/CD28 signaling. While CAR engineered “young” memory T cells are
transferred to the patient, the cells expand and undergo further differentiation
leaving effector memory T cells at the tumor lesion which require additional
signals for being protected from anergy and activation-induced cell death. On
the other hand, those more matured cells have increased cytolytic potential
making them highly effective in the anti-tumor attack. Engineering T cells with
a combined CD28-OX40 CAR which prevents apoptosis of matured CCR7− T
cells is one of the upcoming strategies to solve the situation and to improve
the anti-tumor efficacy in the long-term.
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et al., 2001). In combination with CD28 in a so-called “third
generation” CD28-OX40 CAR, combined costimulation improved
survival and cytolytic activities of CCR7− T cells toward targeted
cancer cells (Hombach et al., 2013). Similar results were obtained
with CD62L− T cells which mature from CCR7− CD62L+ T cells
upon stimulation (Hombach and Abken, 2011). The combination
of costimulatory signals achieves the effect since OX40 alone does
not provide benefit in this context whereas CD28 costimulation
alone, which prevents CCR7+ T cell apoptosis, does not reduce
the number of apoptotic CCR7− cells. Taken together adoptive cell
therapy will benefit from redirecting T cells by a CD28-OX40 CAR
to provide protection from apoptosis when young cells progress
in maturation.
PERSPECTIVES: HOW TO MAINTAIN AN ANTI-TUMOR
RESPONSE IN THE LONG-TERM?
Several factors together are required to rescue matured CAR T cells
for the anti-tumor response in the long-term.
First, any T cell subset converts to effector memory cells upon
repetitive antigen engagement and amplification and in each stage
of maturation requires appropriate costimulation to escape cell
death; consequently, harnessing young T cells with a CD28-OX40
CAR will be beneficial and will rescue CCR7− cells when produced
during an anti-tumor attack.
Second, CCR7− T cells persist in peripheral lesions due to their
inability to re-enter the lymph, thereby increasing the probability
for successful cancer cell killing. To improve their accumulation at
the tumor site T cells were additionally engineered with the CCR2
receptor (Moon et al., 2011). Alternatively, CAR engineered T cells
are injected into the tumor lesion taking advantage of the plethora
of different effector T cell subsets in fighting cancer while circum-
venting the limitations in T cell trafficking. In contrast, i.v. injected
T cells become stuck in the lungs for hours and subsequently
accumulate in liver, spleen, and lymph nodes, while regional appli-
cation produces T cell persistence at the injected tumor site with
only local diffusion within the following days (Parente-Pereira
et al., 2011). The strategy, however, requires good accessibility by
direct puncture or by endoscopy and is currently evaluated in the
treatment of head and neck cancer (EudraCT 2012-001654-25,
NCT01722149) or will be applied to the treatment of cutaneous
lymphoma (EudraCT 2011-003125-10).
Third, effector memory T cells produce increased levels of
pro-inflammatory cytokines and cytolytic molecules, both con-
tributing to improve cancer cell killing. Late memory T cells,
however, are TCR hypo-responsive which is due to an inefficient
formation of the TCR synapse as a result of galectin-3 anchoring
of TCR components. Interestingly, formation of a transgenic CAR
synapse in those cells is not affected making them fully responsive
to CAR targets (Rappl et al., 2012).
Since T cell expansion is mandatory to establish adoptively
transferred T cells in the long-term, sufficient space is provided to
transferred T cells by non-myeloablative lympho-depleting pre-
conditioning followed by IL-2 administration to sustain expan-
sion; other cytokines like IL-7 and IL-15 are also explored (Weber
et al., 2011). Extensive T cell amplification, on the other hand,
produces effector memory T cells which then need to be pro-
tected from activation-induced cell death. Other costimulation
than by CD28 and OX40 may also provide benefit to those cells,
for instance 4-1BB (Song et al., 2011). Co-signaling by 4-1BB
and CD28 may also provide an advantage to matured T cells,
however, needs to be evaluated in detail. The effect of each com-
bination of costimulatory signals, however, cannot be predicted
since the CAR with its linked endodomains provides simulta-
neous signaling while in the physiological situation the signals
occur individually in a well-defined temporal and spatial order.
An elegant solution of the dilemma is the use of virus-specific T
cells which are further matured by the immune system and have
some significant properties needed for effective anti-cancer ther-
apy. These cells obtain survival and costimulatory signals when
engaging virus-infected cells by their TCR. Current trials use
EBV or CMV specific, autologous T cells engineered with a first
or second generation CAR, for instance directed against ErbB2
(NCT01109095), CD30 (NCT01192464), CD19 (NCT00709033;
NCT01475058; NCT01430390; NCT00840853; NCT01195480),
or GD-2 (NCT00085930). Virus-specific T cells are long-lived
in pre-clinical models in vivo, have a great capacity to amplify
and are particularly applied in the context of allogeneic stem cell
transplantation where they protect from virus re-activation and
tumor relapse while having low risk of inducing graft versus host
disease.
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